Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515632 | 0.84 | GRM5 (0.43) | GRM5MAPTPDE10ABRAFIDO1 | |
| SCHEMBL4517225 | 0.83 | BRD4 (0.40) | GRM5MAPTPDE10ABRAF | |
| SCHEMBL4524359 | 0.82 | MAP3K5 (0.42) | GRM5MAPTCCNA2CDK2CCNA1 | |
| SCHEMBL4528975 | 0.81 | GRM5 (0.44) | GRM5MAPTPDE10ABRAFNPC1 | |
| SCHEMBL4513339 | 0.80 | GRM5 (0.48) | GRM5MAPT | |
| SCHEMBL4522150 | 0.79 | GRM5 (0.42) | GRM5MAPTCCNA2CDK2CCNA1 | |
| SCHEMBL4519722 | 0.78 | KDR (0.45) | GRM5MAPTNPC1RAB9ATP53 | |
| SCHEMBL4524435 | 0.76 | LIMK2 (0.50) | NR3C1MAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4514307 | 0.75 | GRM5 (0.40) | GRM5NR3C1 | |
| SCHEMBL4559457 | 0.75 | PIK3CA (0.43) | GRM5CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| CN-101460478-A | Novel bi-aryl amines | NOVARTIS AG (CH) | 2009-06-17 | — | — | CN | disclosed |
| EP-2004624-A1 | NOVEL BI-ARYL AMINES | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113276-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113276-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NAT1, MAOB, CYP2B6 | GRM5 3095/4885NR3C1 1564/4885MAPT 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.